G1 Therapeutics Inc (GTHX)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
GTHX Chart
G1 Therapeutics (GTHX) Reports Q2 Loss, Tops Revenue Estimates
G1 Therapeutics (GTHX) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to earnings of $0.14 per share a year ago.
Why Is G1 Therapeutics (GTHX) Stock Up 66% Today?
G1 Therapeutics (NASDAQ: GTHX ) stock is rocketing higher on Wednesday after the company announced an acquisition deal with Pharmacosmos Group. Pharmacosmos Group has agreed to acquire all outstanding shares of GTHX stock for $7.15 in cash.
G1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025
While small-capitalization biotechnology firms bring much potential to the table, they also represent a source of unpredictability. Nevertheless, for risk-takers, oncology specialist G1 Therapeutics (NASDAQ: GTHX ) appears quite enticing.
G1 Therapeutics Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 1,000 | $10 | $10 | - | - |
G1 Therapeutics Inc (GTHX) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
G1 Therapeutics Inc Profile
| - Industry | - Sector | Mr. John E. Bailey Jr. CEO | NASDAQ (NGS) Exchange | 3621LQ109 CUSIP |
| United States Country | 100 Employees | - Last Dividend | - Last Split | 17 May 2017 IPO Date |
Overview
G1 Therapeutics, Inc. is a biopharmaceutical company that has reached the commercial stage, signaling a significant phase in its journey. Founded in 2008, the company has been devoted to the discovery, development, and commercialization of small molecule therapeutics, primarily focusing on cancer treatment. With its headquarters nestled in Research Triangle Park, North Carolina, G1 Therapeutics has positioned itself at the forefront of cancer research and treatment, aiming to provide innovative solutions for patients grappling with this challenging disease across the United States.
Products and Services
- COSELA
- Trilaciclib
- Partnerships and Licensing Agreements
G1 Therapeutics offers COSELA, a trailblazing therapeutic development designed to mitigate the incidence of chemotherapy-induced myelosuppression in adult patients. This particularly targets those undergoing treatment with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer. COSELA embodies the company’s commitment to improve the quality of life for cancer patients by addressing some of the most debilitating side effects of chemotherapy treatments.
Currently in the spotlight of G1 Therapeutics’ development pipeline is Trilaciclib, undergoing a Phase 3 clinical trial for the treatment of 1L metastatic triple-negative breast cancer (mTNBC). This therapeutic endeavor represents a significant stride towards addressing a critical need within oncology, aiming to offer a viable and effective treatment option for a particularly aggressive form of breast cancer. Additionally, Trilaciclib is being explored in a Phase 2 clinical trial, examined as an antibody-drug conjugate combination trial in mTNBC. Its development pipeline showcases versatility, with completed Phase 2 clinical trials for Neoadjuvant TNBC and 1L Bladder Cancer, highlighting the potential broad applicability of Trilaciclib in cancer treatment.
G1 Therapeutics has forged key partnerships to extend its reach and impact in the fight against cancer. Notably, the company has entered into a licensing agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib in an oral dosage form for various indications in humans. Additionally, a collaboration with Incyclix revolves around the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. A similar agreement is in place with Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. These strategic partnerships not only underscore G1 Therapeutics’ commitment to advancing cancer treatment but also highlight its collaborative approach to bringing novel therapies to market.
